On ECHEMI
Home > Drugs > Calcium folinate tablets

Calcium folinate tablets

Function and Efficacy

Pharmacological action: This product is a formyl derivative of tetrahydrofolate, and is mainly used for the rescue of high-dose methotrexate and other folic acid antagonists. Folic acid is reduced and methylated by dihydrofolate reductase in the small intestinal cells, converted into methyltetrahydrofolate, and then acts as a coenzyme to participate in the synthesis of purine and pyrimidine nucleotides and the conversion of certain amino acids in the body. Methotrexate can bind to dihydrofolate reductase, blocking the conversion of dihydrofolate into tetrahydrofolate, thereby inhibiting the synthesis of thymine nucleotides, DNA, RNA and even proteins. After entering the body, this product is converted into tetrahydrofolate by tetrahydrofolate reductase, which can limit the degree of damage to normal cells caused by methotrexate and reverse the response of methotrexate to the bone marrow and gastrointestinal mucosa, but it has no obvious effect on the neurotoxicity caused by methotrexate that has already occurred.

Ingredients

Calcium folinate

Name Description Content CAS NO. Manufacturer
Calcium folinatcIngredients

This product is a formyl derivative of tetrahydrofolate, mainly used for the rescue of high-dose methotrexate and other folic acid antagonists. It can be converted into tetrahydrofolate by tetrahydrofolate reductase, which can limit the damage of methotrexate to normal cells and reverse the reaction of methotrexate to bone marrow and gastrointestinal mucosa, but it has no obvious effect on the neurotoxicity caused by methotrexate.

More
6035-45-6 6

Appearance

This product is slightly yellow or light yellow tablets.

Indication

1. Used as an antidote for folic acid antagonists (such as methotrexate, pyrimethoprim or trimethoprim). 2. Used to prevent severe toxic effects caused by overdose or high-dose treatment with methotrexate. 3. Also used to treat megaloblastic anemia caused by folic acid deficiency. 4. Used in combination with 5-fluorouracil for advanced colon and rectal cancer.

Usage and Dosage

1. Calcium folinate "rescue" therapy after high-dose methotrexate treatment: The dose of calcium folinate is determined according to the blood concentration of methotrexate. Generally, 24 hours after intravenous injection of methotrexate, calcium folinate 10 mg/m2 is given once every 6 hours for a total of 10 times. If gastrointestinal toxicity occurs, do not inject calcium folinate intrathecally. 2. When methotrexate is not eliminated smoothly or overdose is accidentally used: When methotrexate is accidentally overdosed, calcium folinate should be used as promptly as possible for emergency treatment; when excretion is delayed, calcium folinate should also be used within 24 hours of methotrexate use. Generally, 10 mg of calcium folinate is injected intramuscularly or intravenously every 6 hours until the methotrexate level in the blood is lower than 10-8M (0.01μm

Adverse Reactions

Rarely, allergic reactions such as rash, hives, or asthma may occur occasionally.

Precautions

It is contraindicated in pernicious anemia or megaloblastic anemia caused by vitamin B12 deficiency.

Drug Interactions

Large amounts of folic acid may counteract the anti-epileptic effects of phenobarbital, phenytoin and primidone, increasing the rate of epileptic seizures in some children who are taking anti-epileptic drugs. Preliminary studies in animals and humans have shown that a small amount of folinic acid enters the spinal cord in the form of 5-methylfolate when administered systemically, causing a decrease in the usual blood concentration of methotrexate after intrathecal administration. Therefore, high doses of folinic acid may reduce the effect of intrathecal administration of methotrexate. Folinic acid may increase the toxicity of fluorouracil. This product can be used simultaneously with pyrimethamine or trimethoprim to prevent the latter from causing secondary megaloblastic anemia.

Storage

Sealed, stored in a cool, dark and dry place. +Tentatively two and a half years.

Packaging Specification

25mg

Manufacturer

Changchun Tiancheng Pharmaceutical Co., Ltd.

  • Founded in:

    1992-08-25
  • Address:

    5 km north of Changji Highway, Anlongquan, Changchun
  • Tax NO.:

    91220101605119899X
  • Registered Funds:

    50 million yuan
  • Email:

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.